Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
AIM · NYSE · Biological Products, (No Diagnostic Substances)
Aim Immunotech (AIM) · oqro.io/stocks/AIM · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
$0.1436−0.005 (−3.36%)
Close of Nov 13, 2026, vs Nov 12 · end-of-day, not a live quote
9 routine filings (option exercises, shares withheld for taxes, grants, gifts) are not listed here. Show them
Traded Nov 6 – Nov 11, 2026 · largest single transaction ~$5.4K
Nov 11, 2026~$5.2K · 35K sh @ $0.149
DetailsOfficial recordNov 10, 2026~$5.4K · 39K sh @ $0.138
DetailsOfficial recordNov 9, 2026~$5.1K · 31K sh @ $0.162
DetailsOfficial recordInsider buying
Traded Nov 6 · filed the same day
Since the trade −7.3% · S&P 500 +2.6% · to Nov 13
The CEO of Aim Immunotech paid $3.2K out of pocket for Aim Immunotech shares. Shares held went up 11% with this purchase.
Insider buying
Traded Oct 23 · filed 3 days later
Since the trade −8.1% · S&P 500 −0.7% · to Nov 13
The CEO of Aim Immunotech paid $5.1K out of pocket for Aim Immunotech shares. Shares held went up 20% with this purchase.
Insider buying
Traded Oct 22 · filed 1 day later
Since the trade −10.8% · S&P 500 −1.3% · to Nov 13
The CEO of Aim Immunotech paid $5.1K out of pocket for Aim Immunotech shares. Shares held went up 25% with this purchase.
Traded Sep 14 – Sep 17, 2026 · largest single transaction ~$5K
Sep 17, 2026~$5K · 24K sh @ $0.208
DetailsOfficial recordInsider buying
Traded Jun 13, 2025 · filed 3 days later
The CEO of Aim Immunotech paid $824 out of pocket for Aim Immunotech shares.
Insider buying
Traded Jun 12, 2025 · filed 1 day later
The CEO of Aim Immunotech paid $896 out of pocket for Aim Immunotech shares.
Insider buying
Traded Apr 11, 2025 · filed 12 days later
The CEO of Aim Immunotech paid $50K out of pocket for Aim Immunotech shares. 3 other people at Aim Immunotech bought some too, in the same month. Shares held went up 104% with this purchase.
Insider buying
Traded Apr 11, 2025 · filed 12 days later
An Aim Immunotech director paid $50K out of pocket for Aim Immunotech shares. 3 other people at Aim Immunotech bought some too, in the same month. Shares held went up 196850% with this purchase.
Insider buying
Traded Apr 11, 2025 · filed 12 days later
An Aim Immunotech director paid $5K out of pocket for Aim Immunotech shares. 3 other people at Aim Immunotech bought some too, in the same month. Shares held went up 61% with this purchase.
Insider buying
Traded Apr 4, 2025 · filed 3 days later
Since the trade +51.5% · S&P 500 +49.3% · to Nov 13
The CEO of Aim Immunotech paid $2.6K out of pocket for Aim Immunotech shares. 3 other people at Aim Immunotech bought some too, in the same month.
Insider buying
Traded Apr 4, 2025 · filed the same day
Since the trade +51.5% · S&P 500 +49.3% · to Nov 13
Aim Immunotech's COO, Secretary, Gen. Counsel paid $44 out of pocket for Aim Immunotech shares. 3 other people at Aim Immunotech bought some too, in the same month.
Traded Mar 4 – Mar 5, 2025 · largest single transaction ~$10K
Mar 5, 2025~$6.7K · 50K sh @ $0.1346
DetailsOfficial recordInsider buying
Traded Nov 21, 2024 · filed 61 days later
Since the trade −32.1% · S&P 500 +27.1% · to Nov 13
The CEO of Aim Immunotech paid $4.2K out of pocket for Aim Immunotech shares. 1 other person at Aim Immunotech bought some too, in the same month.
Insider selling
Traded Dec 19, 2024 · filed 1 day laterNot reported under a pre-arranged trading plan
Since the trade −24.8% · S&P 500 +28.7% · to Nov 13
An Aim Immunotech director sold $884 of Aim Immunotech shares. The filing does not indicate a pre-arranged trading plan.
Insider buying
Traded Dec 18, 2024 · filed 1 day later
Since the trade −26.7% · S&P 500 +28.7% · to Nov 13
The CEO of Aim Immunotech paid $4.7K out of pocket for Aim Immunotech shares. 1 other person at Aim Immunotech bought some too, in the same month.
Traded Dec 2, 2024 · largest single transaction ~$2.4K
Dec 2, 2024~$2.4K · 11K sh @ $0.212
DetailsOfficial recordInsider buying
Traded Nov 20, 2024 · filed 1 day later
Since the trade −28.1% · S&P 500 +27.8% · to Nov 13
An Aim Immunotech director paid $16K out of pocket for Aim Immunotech shares. 1 other person at Aim Immunotech bought some too, in the same month. Shares held went up 34% with this purchase.
Traded Nov 20, 2024 · largest single transaction ~$17K
Nov 20, 2024~$17K · 85K sh @ $0.199
DetailsOfficial recordNov 6, 2026~$2K · 13K sh @ $0.158
Sep 16, 2026~$2.3K · 11K sh @ $0.21
DetailsOfficial recordSep 15, 2026~$4.9K · 22K sh @ $0.221
DetailsOfficial recordSep 14, 2026~$1.3K · 5,900 sh @ $0.219
DetailsOfficial recordMar 4, 2025~$5.1K · 44K sh @ $0.115
DetailsOfficial recordMar 4, 2025~$10K · 83K sh @ $0.12
DetailsOfficial recordDec 2, 2024~$0 · 1 sh @ $0.212
DetailsOfficial recordNov 20, 2024~$11K · 60K sh @ $0.183
DetailsOfficial record28 open-market purchases and 1 open-market sale by insiders of AIM between Sep 7, 2019 and today, placed against the company's last 4 earnings releases. The latest on file was filed Aug 10, 2026. The data provider lists the next release for Nov 16, 2026; that date may change.
PurchaseSale30 days before a release30 days after
| Earnings release | 30 days before | On the day | 30 days after |
|---|---|---|---|
| Aug 10, 2026 | None | None | None |
| May 19, 2026 | None | None | None |
| Apr 16, 2020 | None | None | None |
| Oct 7, 2019 | None | None | None |
Companies set trading windows, which usually close shortly before results and reopen after them, and insiders may trade under 10b5-1 plans adopted months earlier. A date alone does not show what a person knew or why they traded. Past release dates are the dates the company filed its 8-K with Item 2.02. An upcoming date, when one is mentioned, comes from the data provider's earnings calendar (Finnhub): it is not a company filing, it is not estimated by OQRO, and it may change. Open-market purchases and sales as reported on Form 4. Largest purchases around earnings, all companies
